Assessing the Risk of a Clinically Significant Infection from a Microneedle Array Patch (MAP) Product
July 28, 2023
By Christine Craig, ValSource Consultant (co-author)
A recently published paper titled, “Assessing the risk of a clinically significant infection from a microneedle array patch (MAP) product,” co-authored by ValSource Consultant Christine Craig, identifies some of the key product and patient-specific factors that may contribute to the risk of infection from a MAP product and provides expert opinions in the context of guidance from regulatory authorities.